Please provide your email address to receive an email when new articles are posted on . Anifromulab had previously been approved in IV form for systemic lupus erythematosus. The decision to approve ...
The FDA has approved Saphnelo (anifrolumab-fnia) for subcutaneous administration in patients with systemic lupus ...
Astrazeneca plc’s anifrolumab has been approved by the FDA for the autoimmune disease systemic lupus erythematosus (SLE), setting up a rivalry with its U.K.-based counterpart Glaxosmithkline plc. The ...
AstraZeneca has completed the resurrection of its anifrolumab drug for systemic lupus erythematosus (SLE) after claiming FDA approval for the drug as an add-on therapy for adults with the autoimmune ...
A new drug for the treatment of adult patients with moderate to severe cases of the most common type of lupus was approved Monday by the U.S. Food and Drug Administration. AstraZeneca's Saphnelo ...
Anifrolumab-fnia, an IFNAR1-blocking monoclonal antibody, is now authorized for weekly subcutaneous self-administration in adult SLE alongside corticosteroids, antimalarials, and/or immunosuppressants ...
If approved, a subcutaneous formulation of anifrolumab would allow patients the ability to self-administer the medication outside of a hospital or clinic setting. The Food and Drug Administration (FDA ...
The new weekly 120 mg SC formulation, supported by TULIP-SC trial results, offers patients with moderate to severe SLE a self-administered alternative to monthly IV infusions.
AstraZeneca has completed the resurrection of its anifrolumab drug for systemic lupus erythematosus (SLE) after claiming FDA approval for the drug as an add-on therapy for adults with the autoimmune ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results